Skip to main content
SpringerLink
Log in

Karzinom des exokrinen Pankreas

  • Chapter
Kompendium Internistische Onkologie

  • 11 Accesses

Zusammenfassung

Häufigkeit: Die Häufigkeit variiert in den westlichen Industrienationen. Sie hat sich aber in USA und den meisten europäischen Ländern zwischen 1930 und 1980 verdoppelt, allerdings flacht der Inzidenzanstieg seit 1970 ab. In den USA ist das Pankreaskarzinom derzeit die vierthäufigste Krebstodesursache.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Almoguera CD, Shibata K, Forrester (1988) Most human carcinomas of the exocrine pancreas contain mutant c-Ki-ras genes. Cell 53: 549

    CAS  Google Scholar 

  • Bakkevold KE, Arnesjo B, Kambestad B (1992) Carcinoma of the pancreas and papilla of Vater: Presenting symptoms signs, and diagnostic related to stage and tumour site. Secand J Gastroenterol 27: 317–325

    Google Scholar 

  • Bakkevold KE, Arnesjo B, Dahl O, Kambestad B (1993) Adjuvant combination chemotherapie ( AMF) following radical resection of carcinoma of the pancreas and papilla of Vater - Results of a controlled, prospective, randomised multicentre study. Eur J Cancer 29A: 698–703

    Google Scholar 

  • Bakkevold KE, Kambestad B (1993) Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater - the prognostic factors influencing the long-term results. A prospective multicentre study. Eur J Surg Oncol 19: 147–161

    Google Scholar 

  • Bakkevold KE, Kambestad B (1993) Morbidity and mortality after radical and palliative pancreatic cancer surgery. Risk factors influencing the short-term-results. Ann Surg 217: 356–368

    Google Scholar 

  • Brennan MF, Kinsella TJ, Casper ES (1993) Cancer of the pancreas. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer principles and practice of oncology. Lippincott, Philadelphia, pp 849–882

    Google Scholar 

  • Carriaga MT, Henson DE (1995) Liver, gallbladder, extrahepatic bile ducts, and pancreas. Cancer 75: 171–190

    Article  PubMed  CAS  Google Scholar 

  • Coia L, Hoffman J, Scher R, Eisenberg B, Paul A, Hanks G (1994) Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Rad Oncol Biol Phys 30: 161–167

    Article  CAS  Google Scholar 

  • Cullinan SA, Moertel CG, Fleming TR et al. (1985) A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 253: 2061–2067

    Article  PubMed  CAS  Google Scholar 

  • Cullinan SA, Moertel CG, Wieand HS et al. (1990) A phase III trial on the therapy of advanced pancreatic carcinoma. Cancer 65: 2207–2212

    Article  PubMed  CAS  Google Scholar 

  • Devesa SS, Blot WJ, Stone BJ et al. (1995) Recent cancer trends in the United States. J Natl Cancer Inst 87: 175–182

    Article  PubMed  CAS  Google Scholar 

  • Friess H, Büchler M (1993) Wachstumsfaktoren beim Pankreaskarzinom: Schlüs- sel für neue Therapiekonzepte der Zukunft? Z Gastroenterol 31: 629–630

    PubMed  CAS  Google Scholar 

  • Garton GR, Gunderson LL, Nagorney DM, Donohue JH, Martin JK, Mcilrath DC, Cha SS (1993) High-Dose preoperative irradiation for locally advanced pancreatic cancer. Int J Rad Oncol Biol Phys 27: 1153–1157

    Article  CAS  Google Scholar 

  • Gastrointestinal Tumor Study Group (1988) Treatment of locally unresectable carcinoma of the pancreas: Comparison of combined-modality therapy (chemotherapie plus radiotherapy) to chemotherapy alone. J Natl Cancer Inst 80: 751–755

    Article  Google Scholar 

  • Gastrointestinal Tumor Study Group (1987) Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 59: 2006–2010

    Article  Google Scholar 

  • Griffin JF, Smalley SR, Jewell W, Paradelo JC, Reymond RD, Hassanein RES, Evans RG (1990) Patterns of failure after curative resection of pancreatic carcinoma. Cancer 66: 56–61

    Article  PubMed  CAS  Google Scholar 

  • Hermanek P (1991) Staging of exocrine pancreatic carcinoma. Eur J Surg Oncol 17: 167–172

    PubMed  CAS  Google Scholar 

  • Höfler H (1994) Prognosefaktoren beim Pankreascarcinom. Chirurg 65: 253–257

    PubMed  Google Scholar 

  • Klempnauer J, Ridder GJ, Bektas H, Pichlmayr R (1995) Surgery for exocrine pancreatic cancer–Who are the 5- and 10-year survivors? Oncology 52: 353–359

    Article  PubMed  CAS  Google Scholar 

  • Levin DL, Connelly RR, Devesa SS (1981) Demographic characteristics of cancer of the pancreas: mortality, incidence, and survival. Cancer 47: 1456–1468

    Article  PubMed  CAS  Google Scholar 

  • Lionetto R, Pugliese V, Bruzzi P, Rosso R (1995) No standard treatment is available for advanced pancreatic cancer. Eur J Cancer 31 A(6): 882–887

    Google Scholar 

  • Lucarott ME, Habib NA, Kelly SB (1991) Clinical evaluation of combined use of CEA, CA 19–9, and CA 50 in the serum of patients with pancreatic carcinoma. Eur J Surg Oncol 17: 51–53

    Google Scholar 

  • Mallison CN, Rake MO, Cocking JB et al. (1980) Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomized multicenter trial. BMJ 281: 1589–1591

    Google Scholar 

  • Moertel CG, Frytak S, Hahn RG et al. (1981) Therapy of locally unresectable pancreatic carcinoma: A randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-FU) and high dose radiation +5-fluorouracil. Cancer 48: 1705–1710

    Article  PubMed  CAS  Google Scholar 

  • Moore M, Andersen J, Burris H, Tarassoff P, Green M, Casper E, Portenoy R, Modiano M, Cripps C, Nelson R, Storniolo A, Hoff D Von (1995) A randomized trial of gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer. Proc ASCO 14: 199 (Abstract 473)

    Google Scholar 

  • Niyikiza C, Andersen JS, Tarassoff PG, Rothenberg ML, Seitz DE, Nelson RL, Moore M, Storniolo AM (1996) Prognostic factors in a randomized trial of gemcitabine (GEM) versus 5-FU as first-line therapy in advanced pancreatic cancer and in pancreatic cancer patients failing 5-FU who receive gemcitabine (GEM) as a palliative therapy. Proc ASCO 15:Abstract 1624

    Google Scholar 

  • Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RCF (1994) Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 81: 882–885

    Article  PubMed  CAS  Google Scholar 

  • Pellegata NS, Losokoot M, Foddie R et al. (1992) Detection of K-ras mutations by denaturating gradient gel electrophoresis: a study on pancreatic cancer. Anticancer Res 12: 1731–1735

    PubMed  CAS  Google Scholar 

  • Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo A-M, Hoff DD Von (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347–353

    Article  PubMed  CAS  Google Scholar 

  • Swope TJ, Wade TP, Neuberger TJ, Virgo KS, Johnson FE (1994) A reappraisal of total pancreatectomy for pancreatic cancer: Results from U.S. Veterans Affairs Hospitals, 1987–1991. Am J Surg 168: 582–586

    Article  PubMed  CAS  Google Scholar 

  • Trede M, Schwall G, Saeger HD (1990) Survival after Pancreatoduodenectomy. Ann Surg 211: 447–458

    Article  PubMed  CAS  Google Scholar 

  • Verweij J, Clavel M, Chevalier B (1994) Paclitaxel (Taxol) and docetaxel ( Taotere ): Not simply two of a kind. Ann Oncol 5: 495–505

    Google Scholar 

  • Wingo PA, Tong T, Bolden S (1995) Cancer statistics 1995. CA Cancer J Clin 45: 830

    Article  Google Scholar 

Download references

Authors
  1. D. Strumberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Wilke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H.-J. Illiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Klempnauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik und Poliklinik, Innere Medizin IV, Abteilung Hämatologie/Onkologie, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Straße 40, D-06120, Halle/Saale, Deutschland

    Hans-Joachim Schmoll (Direktor) (Direktor)

  2. Klinik und Poliklinik für Innere Medizin II, Klinikum der Friedrich-Schiller-Universität Jena, Erlanger Allee 101, D-07740, Jena, Deutschland

    Klaus Höffken (Direktor) (Direktor)

  3. Medizinischen Klinik II, Schwerpunkt Onkologie und Hämatologie, Humboldt-Universität, Universitätsklinikum Charité, Schumannstraße 20/21, D-10117, Berlin, Deutschland

    Kurt Possinger (Direktor) (Direktor)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Strumberg, D., Wilke, H., Illiger, HJ., Klempnauer, J. (1997). Karzinom des exokrinen Pankreas. In: Schmoll, HJ., Höffken, K., Possinger, K. (eds) Kompendium Internistische Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-12175-7_39

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-12175-7_39

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-60830-1

  • Online ISBN: 978-3-662-12175-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation